Journal Article Review Epublish
PubMed: 42665741 DOI: 10.1007/s12265-026-10820-5
The Trajectory of Epigenetic Chromatin Remodeling in Cardiometabolic Disease and its Therapeutic Implications.
J Cardiovasc Transl Res 19(1)
Authors: Mirjana Macvanin, Aleksandra Klisic
Affiliations
- Institute of Chemistry, Technology and Metallurgy, Center for Chemistry, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia.
- University of Montenegro-Faculty of Medicine, Podgorica, Montenegro.
- Center for Laboratory Diagnostics, Primary Health Care Center, Podgorica, Montenegro.
Abstract
The pathogenesis and progression of cardiometabolic diseases (CMD) are intricately linked to epigenetic regulation mediated by chromatin remodeling. Modifications to histones, such as post-translational acetylation and methylation, along with DNA methylation, alter chromatin structure and accessibility, resulting in transient or irreversible alterations in gene expression without accompanying changes in the DNA sequence. Herein, we outline the trajectory of epigenetic chromatin remodeling across various tissues, focusing on the liver-heart axis and the crosstalk between various epigenetic mechanisms in CMD pathogenesis and progression. We provide a list of drugs that target crucial epigenetic enzymes for CMD treatment. Furthermore, we propose possible future directions for the development of effective therapies targeting the crosstalk interaction points of epigenetic mechanisms involved in CMD.
MeSH
Genes, Chromatin, Therapeutics